v3.26.3
Segment Information
 9 Months Ended
Sep. 30, 2026
Segment Information [Abstract]  
SEGMENT INFORMATION

NOTE 13 – SEGMENT INFORMATION

 

Segment Reporting

 

The Company applies the provisions of ASC 280, Segment Reporting. Operating segments are comprised of the components of an entity for which separate information is available to the Company’s chief operating decision maker, or group of decision makers, in determining how to allocate resources and evaluate performance. During the three and nine months ended September 30, 2026, the Company had two reportable segments: Genetic Diagnostic and Quantum Drones.

 

The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer.

 

The accounting policies of the Genetic Diagnostic and Quantum Drones segments are as described in the summary of significant accounting policies. The CODM evaluates the performance of each segment based on segment net loss, using the segment expense information presented below and in Note 12. Segment assets are presented below.

 

The following performance measures were used by the CODM:

 

    Quantum Drones     Genetic Diagnostic     Corporate     Total  
    Three months ended     Three months ended     Three months ended     Three months ended  
    September 30,     September 30,     September 30,     September 30,  
    2026     2025     2026     2025     2026     2025     2026     2025  
Revenue   $ 966,833     $ -     $ -     $ -     $ -     $ -     $ 966,833     $ -  
Cost of revenue     873,243       -       -       -       -       -       873,243       -  
Gross profit     93,590       -       -       -       -       -       93,590       -  
                                                                 
Operating expenses:                                                                
Sales and marketing     287,422       -       -       -       483,728       434,827       771,150       434,827  
Research and development     669,976       -       12,000       20,000       573,053       19,318       1,255,029       39,318  
General and administrative     879,228       -       9,263       15,279       2,040,931       677,311       2,929,422       692,590  
Total operating expenses     1,836,626       -       21,263       35,279       3,097,712       1,131,456       4,955,601       1,166,735  
                                                                 
Other income (expense)     16,701       -       -       -       (74,859 )     (41,299 )     (58,158 )     (41,299 )
Loss from discontinued operations     -       -       -       -       (461,272 )     (1,711,312 )     (461,272 )     (1,711,312 )
Net loss   $ (1,726,335 )   $ -     $ (21,263 )   $ (35,279 )   $ (3,633,843 )   $ (2,884,067 )   $ (5,381,441 )   $ (2,919,346 )

 

    Quantum Drones     Genetic Diagnostic     Corporate     Total  
    Nine months ended     Nine months ended     Nine months ended     Nine months ended  
    September 30,     September 30,     September 30,     September 30,  
    2026     2025     2026     2025     2026     2025     2026     2025  
Revenue   $ 966,833     $ -     $ -     $ -     $ -     $ -     $ 966,833     $ -  
Cost of revenue     873,243       -       -       -       -       -       873,243       -  
Gross profit     93,590       -       -       -       -       -       93,590       -  
                                                                 
Operating expenses:                                                                
Sales and marketing     287,422       -       -       -       2,224,101       2,453,249       2,511,523       2,453,249  
Research and development (including in-process research and development)     5,035,208       -       42,000       76,328       757,142       153,016       5,834,350       229,344  
General and administrative     1,010,683       -       48,942       57,382       8,101,207       2,802,360       9,160,832       2,859,742  
Total operating expenses     6,333,313       -       90,942       133,710       11,082,450       5,408,625       17,506,705       5,542,335  
                                                                 
Other income (expense)     16,701       -       -       -       (81,670 )     (115,141 )     (64,969 )     (115,141 )
Loss from discontinued operations     -       -       -       -       (4,001,819 )     (5,744,594 )     (4,001,819 )     (5,744,594 )
Net loss   $ (6,223,022 )   $ -     $ (90,942 )   $ (133,710 )   $ (15,165,939 )   $ (11,268,360 )   $ (21,479,903 )   $ (11,402,070 )

 

    Quantum Drones     Genetic Diagnostic     Corporate     Total  
    September 30,     December 31,     September 30,     December 31,     September 30,     December 31,     September 30,     December 31,  
Balance Sheet   2026     2025     2026     2025     2026     2025     2026     2025  
Total assets   $ 10,940,177     $ -     $ 2,964,411     $ 4,625,794     $ 4,860,697     $ 701,602     $ 18,765,285     $ 5,327,396